Need professional-grade analysis? Visit stockanalysis.com
$5.29B
N/A
87
N/A
Celcuity LLC (CELC) trades on United States in USD. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at $122.46, down 2.23% from the previous close.
Over the past year, CELC has traded between a low of $10.12 and a high of $125.25. The stock has gained 1001.3% over this period. It is currently 1110.1% above its 52-week low.
Celcuity LLC has a market capitalization of $5.29B.
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). It also engages in developing of CELsignia diagnostic platform. The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is based in Minneapolis, Minnesota.
Side-by-side comparison against top Healthcare peers.